Credelio Plus for Dogs 50.1-100 lbs (22-45 kg)

Description

Credelio Plus for Dogs 50.1-100 lbs (22-45 kg), containing 900 mg lotilaner and 33.75 mg milbemycin oxime, delivers comprehensive flea, tick, heartworm, and intestinal worm control through a single monthly chewable tablet calibrated for large-breed dogs that have exceeded the 25.1–50 lbs band. This is the highest single-tablet weight variant in the Credelio Plus range; dogs exceeding 100 lbs require a combination of tablets confirmed by a veterinarian.

Recommended for

Dogs weighing 50.1–100 lbs (22–45 kg) from 8 weeks of age.

Indication/Coverage

For dogs suffering from, or at risk from, mixed parasitic infections, the indications for this variant are as follows:

• Flea treatment and prevention (Ctenocephalides felis, adults): lotilaner inhibits GABA-gated chloride channels selectively in invertebrate nervous systems, producing systemic flea kill within hours of reaching peak plasma concentration.
• Flea allergy dermatitis prevention: sustained elimination of adult fleas prevents the repeated cutaneous allergen challenge that perpetuates allergic dermatitis in sensitised large-breed dogs.
• Tick treatment and prevention (Ixodes scapularis, Ixodes holocyclus, Rhipicephalus sanguineus, Amblyomma americanum, Dermacentor variabilis, adults): lotilaner reaches attached ticks through systemic circulation, disrupting nervous system function following feeding initiation.
• Heartworm disease prevention (Dirofilaria immitis, L3/L4 larvae): milbemycin oxime clears infective larvae deposited during the preceding 30-day interval, maintaining prophylactic coverage in large-breed dogs dosed on a consistent monthly schedule.
• Roundworm treatment (Toxocara canis, immature adults and adults): milbemycin oxime impairs neuromuscular transmission in Toxocara canis at the dose calibrated for this weight band, effective across immature and mature stages.
• Hookworm treatment (Ancylostoma caninum, immature adults and adults): active against both developmental stages of Ancylostoma caninum at the labeled monthly dose for dogs weighing 50.1–100 lbs.
• Whipworm treatment (Trichuris vulpis, adults): milbemycin oxime eliminates adult Trichuris vulpis within the standard monthly dosing cycle at the concentration established for this weight class.

Key Benefits

The following reflects labeled performance data for Credelio Plus for Dogs 50.1–100 lbs:

• Large-breed entry point: Labeled from 50.1 lbs (22 kg) at 8 weeks of age, this tablet addresses the full parasite burden profile of large-breed dogs transitioning from the 25.1–50 lbs variant.
• Single-product parasite management: One monthly dose covers fleas, five tick species, Dirofilaria immitis larvae, and three intestinal nematode genera, eliminating the requirement for concurrent antiparasitic products in most large-breed prevention protocols.
• Systemic ectoparasiticide delivery: Lotilaner reaches ectoparasites through bloodstream absorption after ingestion, removing the dependency on coat coverage area, application precision, or topical residue persistence that spot-on products require.
• Rapid flea kill at large-dog doses: Greater than 98% flea elimination is achieved within 12 hours of administration in fed dogs, including at the higher absolute doses applicable to large breeds.
• Uninterrupted heartworm prevention: Each tablet eliminates Dirofilaria immitis L3 and L4 larvae acquired over the preceding month, sustaining continuous prophylactic coverage when the 30-day interval is observed without exception.
• Multi-stage intestinal worm control: Milbemycin oxime acts against immature adults and adults of Toxocara canis and Ancylostoma caninum, and adults of Trichuris vulpis, addressing the full clinically significant nematode spectrum in large working and companion breeds.
• Oral chewable for large breeds: The flavored tablet is appropriate for large dogs that resist prolonged handling required for spot-on application, or breeds with dense double coats where consistent skin contact for topical products is difficult to achieve.
• 30-day coverage per tablet: A single dose maintains active protection across all labeled indications for one calendar month, provided the dosing interval does not exceed 30 days at any cycle.

Caution

Hazards to Humans

Keep out of reach of children. Avoid ingestion and direct eye contact; flush eyes with running water immediately if exposure occurs. Wash hands thoroughly with soap and water following tablet handling or administration. Prevent contact between the product and food preparation surfaces or any food intended for human consumption.

Hazards to Domestic Animals

Administer orally to dogs only; do not use in cats or other species. This variant is labeled for dogs from 50.1 lbs (22 kg) at a minimum age of 8 weeks. Consult a veterinarian before administering to debilitated, aged, pregnant, or lactating animals. Lotilaner is an isoxazoline-class compound; the FDA has linked this class to neurological adverse reactions, including tremors, ataxia, and seizures, in a subset of dogs. Dogs with any history of seizures or neurological disorders require veterinary assessment before use. Rare individual sensitivity reactions have been documented. Exercise caution when co-administering with medications that are P-glycoprotein substrates.

Possible Side Effects:

Monitor your dog after each administration of Credelio Plus 50.1–100 lbs, with particular attention following the first dose in animals with no prior exposure to lotilaner or milbemycin oxime.

Gastrointestinal reactions:

• Vomiting: The most commonly reported post-dose event in clinical trials; typically manifests within a few hours of administration and resolves without treatment in the majority of large-breed subjects.
• Diarrhea: Observed in a proportion of clinical subjects; self-limiting in most instances and does not warrant product discontinuation in the absence of persistent or worsening signs.
• Inappetence: Transient reduction in appetite reported post-administration in some dogs, generally resolving within 24 hours without requiring intervention.

Systemic reactions:

• Lethargy: A temporary decrease in activity level has been documented following administration; expected to resolve spontaneously within one day in uncomplicated cases.
• Pruritus: Skin irritation not attributable to an active parasite infestation has been reported in a small subset of dogs; spontaneous resolution is the typical clinical course.

Neurological reactions (isoxazoline class alert):

• Tremors, ataxia, or seizures: The FDA has issued a class-level safety communication for isoxazoline compounds, including lotilaner. These reactions are infrequent but present in post-market surveillance data; large-breed dogs with pre-existing neurological conditions carry elevated risk and require veterinary assessment before use.

Consult a veterinarian immediately if any adverse reaction fails to resolve, escalates in severity, or involves neurological signs. For adverse event reporting, contact Elanco Animal Health directly.